Skip Navigation
ChemIDplus Lite•Browse•Advanced

Substance Name: Ancitabine hydrochloride [JAN]
RN: 10212-25-6
UNII: 3T6920M469
InChIKey: KZOWNALBTMILAP-JBMRGDGGSA-N

Note

  • Congener of CYTARABINE that is metabolized to cytarabine and thereby maintains a more constant antineoplastic action.

Molecular Formula

  • C9-H11-N3-O4.Cl-H

Molecular Weight

  • 261.6638
 

Classification Codes

  • Antimetabolites
  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents
  • Drug / Therapeutic Agent
  • Human Data
  • Mutation Data
  • Reproductive Effect
* denotes mobile formatted website

Links to Resources

NLM Resources (File Locators)

Other Resources (Internet Locators)


Search for this InChIKey on the Web

Names and Synonyms

Results Name

  • Ancitabine hydrochloride [JAN]

Name of Substance

  • Ancitabine hydrochloride
  • Ancitabine hydrochloride [JAN]

Synonyms

  • 1-beta-D-Arabinofuranosylcytosine, 2,2'-anhydro-, hydrochloride
  • 1beta-D-Arabinofuranosylcytosine, 2,2'-anhydro-, hydrochloride
  • 2,2'-Anhydro-1-beta-D-arabinofuranosylcytosine hydrochloride
  • 2,2'-Anhydro-1beta-D-arabinofuranosylcytosine hydrochloride
  • 2,2'-Anhydroarabinosylcytosine hydrochloride
  • 2,2'-Anhydroaracytidine hydrochloride
  • 2,2'-Anhydrocytarabine hydrochloride
  • 2,2'-Anhydrocytidine hydrochloride
  • 2,2'-Cyclocytidine hydrochloride
  • 2,2'-Cyclocytidine, monohydrochloride
  • 2,2'-O-Cyclocytidine hydrochloride
  • Ancitabin HCl
  • Ancitabin hydrochlorid
  • Ancitabine hydrochloride
  • Cyclo-cmp hydrochloride
  • Cyclocytidine
  • Cyclocytidine hydrochloride
  • Cytosine, 1-beta-D-arabinofuranosyl-2,2'-anhydro-, hydrochloride
  • Cytosine, 1beta-D-arabinofuranosyl-2,2'-anhydro-, hydrochloride
  • EINECS 233-515-6
  • NSC 145668
  • NSC-145668
  • O-2,2'-Cyclocytidine monohydrochloride
  • OCTD hydrochloride
  • UNII-3T6920M469

Systematic Names

  • 2,2'-Anhydro-1-beta-D-arabinofuranosylcytosine hydrochloride
  • 6H-Furo(2',3':4,5)oxazolo(3,2-a)-pyrimidine-2-methanol, 2,3,3a,9a-tetrahydro-3-hydroxy-6-imino-, monohydrochloride, stereoisomer
  • 6H-Furo(2',3':4,5)oxazolo(3,2-a)pyrimidine-2-methanol, 2,3,3a,9a-tetrahydro-3-hydroxy-6-imino-, monohydrochloride, (2R-(2alpha,3beta,3abeta,9abeta))- (9CI)

Registry Numbers

CAS Registry Number

  • 10212-25-6

FDA UNII

  • 3T6920M469

System Generated Number

  • 0010212256

Molecular Formulas

Molecular Formula

  • C9-H11-N3-O4.Cl-H

Molecular Formula Fragments

  • C9-H11-N3-O4
  • Cl-H
  • COMPONENT

Structure Descriptors

InChI

InChI=1S/C9H11N3O4.ClH/c10-5-1-2-12-8-7(16-9(12)11-5)6(14)4(3-13)15-8;/h1-2,4,6-8,10,13-14H,3H2;1H/t4-,6-,7+,8-;/m1./s1

InChIKey

KZOWNALBTMILAP-JBMRGDGGSA-N

Smiles

Cl.OC[C@H]1O[C@@H]2[C@@H](OC3=NC(=N)C=CN23)[C@@H]1O

Toxicity

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
dog LD50 intravenous 344mg/kg (344mg/kg) GASTROINTESTINAL: NAUSEA OR VOMITING Oyo Yakuri. Pharmacometrics. Vol. 8, Pg. 353, 1974.
monkey LD50 intravenous 1045mg/kg (1045mg/kg) GASTROINTESTINAL: NAUSEA OR VOMITING

GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS

BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY)		 Oyo Yakuri. Pharmacometrics. Vol. 8, Pg. 353, 1974.
mouse LD50 intraperitoneal 2528mg/kg (2528mg/kg)   National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
mouse LD50 intravenous 800mg/kg (800mg/kg)   Drugs in Japan Vol. 6, Pg. 55, 1982.
mouse LD50 oral > 7gm/kg (7000mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 359, 1979.
mouse LD50 subcutaneous 4050mg/kg (4050mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 359, 1979.
rat LD50 intraperitoneal 3800mg/kg (3800mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 359, 1979.
rat LD50 intravenous 820mg/kg (820mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 359, 1979.
rat LD50 oral > 7gm/kg (7000mg/kg)   Drugs in Japan Vol. -, Pg. 86, 1990.
rat LD50 subcutaneous > 5500mg/kg (5500mg/kg)   Gekkan Yakuji. Pharmaceuticals Monthly. Vol. 21, Pg. 359, 1979.
women TDLo subcutaneous 120mg/kg (120mg/kg) BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE

VASCULAR: BP LOWERING NOT CHARACTERIZED IN AUTONOMIC SECTION

GASTROINTESTINAL: NAUSEA OR VOMITING		 Cancer Treatment Reports. Vol. 62, Pg. 455, 1978.